When most people develop a headache, they can rely on a number of over-the-counter drugs to treat the problem. In most circumstances, these medications will alleviate the pain within a reasonable amount of time. Unfortunately, migraines are not regular headaches. A migraine can last anywhere from 4-72 hours, with chronic sufferers experiencing them more than 15 days a month. In addition to the debilitating pain that characterizes the condition, migraines are often accompanied with nausea, auras, and sensitivities to light and sound. Approximately 730 million people suffer from migraines worldwide, making it the most common neurological condition today. Given the number of afflicted people, we would assume that there would exist a variety of drugs and therapies to treat and cure them. The reality couldn’t be further from the truth.
As technology advances, so does our ability to collect data from experimental assays and procedures. But the more data we collect, the more important it becomes to manage the information effectively. The sad reality is that we can easily get overwhelmed by the large volume, finding ourselves unable to use the accumulated knowledge to our advantage. However, the ability to access and mine huge swaths of data is necessary to drive advances in various industries. Let’s look at the Human Genome Project as an example. Because of this multimillion dollar collaborative effort, we now know the exact sequence that encodes human DNA. With that information, scientists can unlock the mechanisms behind specific biological processes in the body, in the hopes of developing therapies for various diseases and conditions.
As Pharmaceutical/Biotech (Bio-Pharma) companies look for opportunities to accelerate innovation, continuous improvement is a strategic imperative. To fast-track innovation, companies need to be open to new ideas and have awareness of new and emerging systems and technologies.
Does your organization have the capacity for global expansion? As biotech and pharmaceutical companies pursue opportunity in maturing markets and emerging economies, they rely on commercial solutions to globally expand what has become an evolving vendor ecosystem. But opportunity has its price. Increasing the use of external resources to achieve clinical advancements and healthcare discoveries requires the best practices for managing the complexities of R&D and therapeutic innovation. Enterprises within the life sciences industries looking to squeeze the most out of their investments as they expand into new markets face the ultimate challenge: improve operational excellence to better deliver new therapies while minimizing and regulatory risk and cost.
Quality management remains a top concern of many life sciences companies. How do they streamline quality processes to minimize bottlenecks and speed up the release cycle to gain advantage in today’s competitive pharmaceutical market? Even more importantly, how do they achieve these goals while keeping costs down in order to […]
As an industry actively transforming itself in the pursuit of reestablishing long term sustainability, life sciences organizations are just beginning to embrace true digital transformation. The goal is to deploy a more holistic strategy that supports a much broader organizational approach to transformation than the current incremental focus on near term technological innovation, operational efficiency and the externalization of non-core competencies common in industry transformation efforts today.
The process of making biologics requires scientists to take living cells and transform them into desirable, purified products. These processes are usually divided into two categories: upstream processes and downstream processes. The challenge of biologics is that they are inherently “difficult to characterize, produce, and reproduce than most traditional pharmaceuticals.” Moreover, slight changes in the quality of raw materials, temperature or other factors, can significantly affect the medicines’ “quality, safety, or efficacy.” Focusing on standardized upstream processing could improve the ability of companies to maximize their gains.
We’ve previously discussed how Millennials have transformed the CPG, food and beverage markets. From an intense focus on sustainability and eco-friendliness to an interest in a wider range of flavors, this consumer demographic has more than proven the power of their buying dollars. Now, we’re seeing their preferences affect a specific corner of the food market: snack products. Because Millennials tend to live active, on-the-go lifestyles, they don’t necessarily have time to sit down for a big meal. Instead, they often graze by eating smaller portions more frequently throughout the day. The proliferation of conveniently packaged foods on grocery stores reflects this trend. Despite their influence, however, we cannot concentrate solely on Millennials. The Baby Boomer generation remains a significant consumer base, and their overall desire for healthy-for-you products has also reached the snack food category. When combined with the Millennial preference toward foods with natural ingredients, is it any surprise that we’re witnessing a growing demand for organic food and snack products?
The following is a guest post by Thomas Bentz, who is part of the Brand Marketing team at Dassault Systèmes. To download the solution brief for Designed to Cure, click here. The drug development process has become increasingly expensive and focused on improved returns on investment. With average development taking […]
Since their invention, sticky notes have become a staple item in everyone’s office supply closet. Households use them as a means to exchange messages while financial workers use them to flag important items for their clients. Who knew the ability to temporarily affix a small piece of paper onto another […]